<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412515</url>
  </required_header>
  <id_info>
    <org_study_id>C06-46</org_study_id>
    <nct_id>NCT01412515</nct_id>
  </id_info>
  <brief_title>A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma</brief_title>
  <official_title>A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Classic Kaposi's sarcoma (CKS) is an angioproliferation associated with human herpes virus 8
      (HHV8), which sometimes requires systemic treatment. Rapamycin and everolimus are mTOR
      inhibitors. The PI3K-AKT-mTOR pathway is activated in CKS.The aim of this study is to
      evaluate the rate of clinical response and tolerance to everolimus 10mg/d in CKS. Patients
      suffering from CKS will be enrolled in a multicenter two-stage phase II trial. At inclusion,
      all patients will have at least 10 lesions or more than one limb or 3% of body surface
      affected, in the absence of symptomatic visceral CKS. The primary endpoint is objective
      response to everolimus after 6 months therapy (complete or partial response per ACTG
      criteria). The trial is planned using Simon's minimax two-stage design to demonstrate a
      response rate of 50% as compared to 20% with type I error rate 2.5% and power of 90%.
      Accordingly, 11 patients will to be enrolled in the first stage and provided at least 3
      patients responded, 15 patients will be accrued in a second stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is objective response to everolimus after 6 months therapy (complete or
      partial response per ACTG criteria).

      Secondary endpoints are response according to physician global assessment, lesions size ,
      lesions infiltration, lymphedema, tolerance, pharmacodynamic (pathologic, angiogenic and
      lymphangiogenic biomarkers, HHV8 viral load sequential evaluation in the lesions,
      pharmacokinetic evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    results from interim analysis conducted to study interruption
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response to everolimus after 6 months therapy</measure>
    <time_frame>duration of study 30 months</time_frame>
    <description>objective response to everolimus after 6 months therapy (complete or partial response per ACTG criteria).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response according to physician global assessment, lesions size , lesions infiltration</measure>
    <time_frame>30 months</time_frame>
    <description>response according to physician global assessment, lesions size , lesions infiltration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Kaposi Sarcoma</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus 10 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>everolimus per os 10mg per day</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologic confirmed classic or endemic KS (non transplant non HIV patients) &gt; 18 Years old
        at least 10 lesions or more than one limb or 3% of body surface affected, in the absence of
        symptomatic visceral KS Presence of at least 4 targets lesions &gt; 5mm At least 4 weeks wash
        out from any KS specific therapy ECOG &lt; 2

        Exclusion Criteria:

        immunosupressive regimen patients HIV positive creatinine clearance &lt;40ml/mn,AST ALT&gt;3N,
        neutropénia&lt;1500, thrombopenia&lt;150000, anemia&lt;8g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celeste Lebbé, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mTOR inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

